[Pemetrexed combined DDP in the treatment of advanced non-small cell lung cancer: a case report and literature review].

BACKGROUND AND OBJECTIVE: The aim of this study is to integrate with literature review, and explore the value of treatment of advanced non-small cell lung cancer with second line. METHODS: For the metastatic progressive non-small cell lung adenocarcinoma patient, the evaluation of efficacy for complete response (CR) with endostar combined GC, the sequential treatment with gefitinib, used pemetrexed combined DDP as the second line treatment, followed up and observed with the progression free survival (PFS) and survival time of patient. RESULTS: Pemetrexed combined DDP in the treatment of 5 cycles, the evaluation of lung cancer efficacy for CR, bone metastasis was steady, PFS was 6.6 months, survival time is 22 months now, improved the quality of living life. CONCLUSIONS: For advanced non-small cell lung adenocarcinoma recurrence and metastasis, after the treatment of first line and maintenance therapy, selecting adequately pemetrexed combined DDP, as the second line treatment, can prolong the lifetime and improve the quality of life.